Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings
Johnson & Johnson stock has delivered a 69.3% total return over the past five years, while current valuation checks send a mixed message, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside and earnings-based multiples looking less generous.
- Over the last five years, Johnson & Johnson has returned 69.3%, which puts more focus on whether today’s price still offers a margin of safety.
- Progress in higher value medicines, including recent U.S. FDA Priority Review for amivantamab in head and neck cancer, can support cash flow expectations, while ongoing talc litigation and the proposed US$5.5b settlement may weigh on how investors assess long term liabilities.
- The valuation checks are mixed rather than clear cut, with Johnson & Johnson screening as undervalued on some measures but scoring only 3 out of 6 on the broader set of tests.
The issue now is whether the current share price already reflects Johnson & Johnson’s intrinsic value or if the DCF-based estimate of undervaluation still leaves room for further upside.
Find out why Johnson & Johnson's 53.3% return over the last year is lagging behind its peers.
Is Johnson & Johnson a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model uses projected cash flows to estimate what Johnson & Johnson could be worth today. For Johnson & Johnson, the latest twelve month free cash flow sits at about $21.7b. The model reflects an assumption that those cash flows continue to grow over time rather than contract.
Based on these assumptions, the DCF analysis points to an intrinsic value of about $364 per share, which is roughly 28.8% above the current share price. The proposed $5.5b talc settlement helps explain why the market remains cautious, yet the stock price still sits below the level implied by this cash flow profile.
Overall, the discounted cash flow analysis suggests that Johnson & Johnson stock currently appears undervalued on this basis.
Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 28.8%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Is Johnson & Johnson Getting Expensive on Earnings?
The P/E ratio suits Johnson & Johnson because earnings are a key focus for mature, cash-generative healthcare companies. On this measure, Johnson & Johnson currently trades on a P/E of about 29.7x. That sits well above the Pharmaceuticals industry average of roughly 17.1x, even though it is lower than the peer group average of about 47.2x.
This gap suggests investors are willing to pay a premium price for each dollar of Johnson & Johnson earnings compared with the broader industry. The ongoing talc litigation and proposed US$5.5b settlement are still in view, yet the stock does not trade at a discount that reflects elevated legal uncertainty. Based on the P/E comparison, Johnson & Johnson screens as expensive relative to typical Pharmaceuticals peers.
On the P/E multiple, Johnson & Johnson stock appears more highly valued than the wider Pharmaceuticals industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Johnson & Johnson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Johnson & Johnson sit between the DCF upside case and the richer P/E multiple, and explain what assumptions about Johnson & Johnson's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each Narrative links a fair value estimate to a specific set of potential catalysts and risks so you can track which version of Johnson & Johnson's story appears to be unfolding over time.
Community views on Johnson & Johnson sit quite far apart, with one side focused on the new drug and MedTech cycle and the other more focused on valuation and defensiveness.
Bull case: roughly fairly valued
"Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity…"
Read the full Bull Case to see why Johnson & Johnson could be undervalued
Bear case: 5% overvalued
"At ~22× earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow…"
Read the full Bear Case to see why Johnson & Johnson could be overvalued
Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!
The Bottom Line
Johnson & Johnson sits in a valuation tug of war. The Discounted Cash Flow (DCF) intrinsic value estimate signals undervaluation, while the earnings multiple points to an overvalued stock compared with typical Pharmaceuticals peers, and the broader checks look mixed rather than strong. That gap largely comes down to how much weight you put on long term cash flows versus current market expectations and sentiment around growth and litigation risk. The key question from here is whether cash generation and legal outcomes ultimately justify a higher multiple, or whether the present premium on earnings already reflects the best case for Johnson & Johnson.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com